Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes.
Nicklas Järvelä JohansenThomas Fremming DejgaardAsger LundCamilla SchlüntzBolette HartmannJens J HolstTina VilsbøllHenrik U AndersenFilip K Krag KnopPublished in: Diabetes, obesity & metabolism (2021)
Despite an exenatide-induced body weight reduction, no changes in bone metabolism were observed with exenatide added to insulin therapy in type 1 diabetes after 26 weeks.